IVIg vs placebo
Survival time · NSTI
1 finding from 1 review
- Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes onlyno estimate extracted1 study · 100 participantsLow
Findings
What do systematic reviews say?
311 questions · 322 findings · 24 reviews · Headline outcomes only
No studies found 78 · 24.2%GRADE not reported 12 · 3.7%Very low 76 · 23.6%Low 76 · 23.6%Moderate 65 · 20.2%High 15 · 4.7%
IVIg vs placebo
Assessment of long‐term morbidity · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
IVIg vs placebo
All‐cause mortality · NSTI
Intravenous immunoglobulin showed no clear difference in mortality compared with placebo (low certainty).
1 finding from 1 review
- Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes onlyRR 1.17 [0.42, 3.23]1 study · 100 participantsLow
IVIg vs placebo
Muscle strength · people with inclusion body myositis
2 findings from 1 review
- no estimate extracted3 studies · 78 participantsGRADE not reported
- no estimate extractedStudies not reportedNo studies found
IVIg vs placebo
Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
IVIg vs placebo
Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
IVIg vs placebo
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
IVIg vs placebo
Significant adverse events · people with inclusion body myositis
1 finding from 1 review
- no estimate extracted3 studies · 78 participantsGRADE not reported
Summary of findings table for oral immunoglobulin vs control
Definite necrotizing enterocolitis (NEC) during study period · preventing necrotizing enterocolitis in preterm and low birth weight neonates
Summary of findings table for oral immunoglobulin showed no clear difference in definite necrotizing enterocolitis (NEC) during study period compared with control (low certainty).
1 finding from 1 review
- Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth weight neonates 2016 · Cochrane Headline outcomes onlyRR 0.84 [0.57, 1.25]3 studies · 1840 participantsLow
Summary of findings table for oral immunoglobulin vs control
Definite necrotizing enterocolitis (NEC) during study period ‐ IgA/IgG · preventing necrotizing enterocolitis in preterm and low birth weight neonates
It is very uncertain whether summary of findings table for oral immunoglobulin changes definite necrotizing enterocolitis (NEC) during study period ‐ IgA/IgG compared with control (very low certainty).
1 finding from 1 review
- Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth weight neonates 2016 · Cochrane Headline outcomes onlyRR 0.08 [0, 1.39]1 study · 179 participantsVery low
Summary of findings table for oral immunoglobulin vs control
Definite necrotizing enterocolitis (NEC) during study period ‐ IgG · preventing necrotizing enterocolitis in preterm and low birth weight neonates
Summary of findings table for oral immunoglobulin showed no clear difference in definite necrotizing enterocolitis (NEC) during study period ‐ IgG compared with control (low certainty).
1 finding from 1 review
- Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth weight neonates 2016 · Cochrane Headline outcomes onlyRR 0.95 [0.63, 1.42]2 studies · 1661 participantsLow
Summary of findings table for oral immunoglobulin vs control
Definite NEC after study period · preventing necrotizing enterocolitis in preterm and low birth weight neonates
It is very uncertain whether summary of findings table for oral immunoglobulin changes definite NEC after study period compared with control (very low certainty).
1 finding from 1 review
- Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth weight neonates 2016 · Cochrane Headline outcomes onlyRR 1.3 [0.47, 3.6]2 studies · 1661 participantsVery low
Summary of findings table for oral immunoglobulin vs control
NEC‐related surgery during study period · preventing necrotizing enterocolitis in preterm and low birth weight neonates
It is very uncertain whether summary of findings table for oral immunoglobulin changes NEC‐related surgery during study period compared with control (very low certainty).
1 finding from 1 review
- Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth weight neonates 2016 · Cochrane Headline outcomes onlyRR 0.21 [0.02, 1.75]2 studies · 311 participantsVery low
Summary of findings table for oral immunoglobulin vs control
NEC‐related deaths during study period · preventing necrotizing enterocolitis in preterm and low birth weight neonates
It is very uncertain whether summary of findings table for oral immunoglobulin changes NEC‐related deaths during study period compared with control (very low certainty).
1 finding from 1 review
- Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth weight neonates 2016 · Cochrane Headline outcomes onlyRR 1.1 [0.47, 2.59]3 studies · 1840 participantsVery low
IVIg vs acetylsalicylic acid (ASA)
Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with acetylsalicylic acid (ASA) (moderate certainty).
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyOR 0.6 [0.41, 0.87]11 studies · 1437 participantsModerate
IVIg vs different infusion regimens of IVIG
Acute coronary syndrome · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
IVIg vs different infusion regimens of IVIG
Duration of fever · people undergoing initial treatment for KD
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 992 participantsLow
IVIg vs different infusion regimens of IVIG
Need for extra treatment · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) may leads to lower need for additional treatment (up to 6 months) compared with different infusion regimens of IVIG (low certainty).
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyOR 0.29 [0.1, 0.88]4 studies · 1125 participantsLow
IVIg vs different infusion regimens of IVIG
Duration of hospital stay MCID: 1 day absolute difference · people undergoing initial treatment for KD
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 752 participantsLow
IVIg vs different infusion regimens of IVIG
Mortality (all‐cause) (up to 7 weeks) · people undergoing initial treatment for KD
1 finding from 1 review
- Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 549 participantsModerate